Skip to content

EV / sales at other companies

AdaptHealth logo
AdaptHealthAHCO
1.1×0.0×
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
0.6×-0.1×
The Pennant Group, Inc. logo
The Pennant Group, Inc.PNTG
1.5×-0.1×
ResMed logo
ResMedRMD
5.8×-0.7×
UFP Technologies logo
UFP TechnologiesUFPT
2.7×-0.5×
Merit Medical Systems logo
Merit Medical SystemsMMSI
2.9×-1.9×

Other financials

Income statement

See full
Revenue$75.4M+27.5%
Gross profit$42.8M+28.7%
Operating income$4.3M+11.8%
Net income$2.6M-1.6%
EPS (diluted)$0.060.0%

Balance sheet

See full
Cash & equivalents$9.8M-3.9%
Total debt$12.4M+84.0%
Total equity$143.9M+6.8%
Total assets$197.4M+10.8%

Cash flow

See full
Operating cash flow$8.1M+183%
CapEx$6.7M-56.6%
Free cash flow$1.4M+111%

Valuation

See full
Market cap$448.16M+71.3%
Enterprise value$450.83M+74.6%
P/E30.1×+8.8×
P/S1.6×+0.4×

Profitability

See full
Gross margin57.6%-1.1pp
Operating margin8.2%-0.2pp
Net margin5.2%-0.1pp
FCF margin9%

Returns & leverage

See full
Return on equity10.7%+0.9pp
Debt / equity0.1×0.0×
Current ratio1.2×-0.2×

Where this comes from

Calculated from Viemed Healthcare, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Viemed Healthcare, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viemed Healthcare, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viemed Healthcare, Inc.'s EV / sales?
Viemed Healthcare, Inc. (VMD) reported EV / sales of 1.3× in Q1 2026.
How has Viemed Healthcare, Inc.'s EV / sales changed year-over-year?
Viemed Healthcare, Inc.'s EV / sales increased by 2.3% year-over-year, from 1.2× to 1.3×.
What is the long-term trend for Viemed Healthcare, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Viemed Healthcare, Inc.'s EV / sales has grown at a -13.2% compound annual growth rate (CAGR), from 2.1× to 1.1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.